Drug Discovery and Clinical Research

So all in the delay design of a high control, um, we should, but it's very How is there a way in the drug adoption process that you're able to ensure affordability in the future when those drugs come out? I think it's a really incredible avenue for treatment. So like if something happened, even occurs, how much is the thing that cost? Specifically for my area of. Specifically for like for year drugs. Yeah, that's such an excellent question. And, um, probably not my area of speculation. Um, so I think one way that we might be able to do that is by demonstrating that there's a larger address For a breaker drug, and so that makes the economics more favorable for a company. Not only does it incentivize their initial investment getting to participate in pre-carry drug discovery, but perhaps it impacts the pricing of a drug if there are more patients that can be reached so that they can get a return on their investment for all of the risk that is involved in the drug discovery. But let's just make My question is, it's also related with Josh talked about, um, particularly the genetic profile with other, like, character, other drugs, other cancers, is that kind of like you're saying? Yeah. I mean, that's something like, I guess, is that just on clinical background? I don't think that one patient they were able to do that. Is that something that's more available for like correct complications in that kind of medical design we are? Yeah, absolutely. I'm sure document Speak to this as a clinician, uh, on the clinical front, but I think that's an important part of guiding the character is it's getting that super profile and if possible sequencing and RNA sequencing to get a further picture because we know that more targeted, um, sequencing panels usually aren't as important for Cordoma as they are for some others. But but that can potentially guide, um, sort of, you know, all label, um, you know, label drug recurrencing opportunities for paid for current patients, and all the things that back into the slightly, you know, forcing out future patients from a scientific perspective. That is, you know, exactly a way of identifying new target vulnerabilities. Um, in Canvas is by the program. I think we've invested a tremendous amount of money for the past five or six years in, in not only genomic sequencing, but multi-genomic sequencing. And pushing all of these data layers together to try to understand what aberration in the biology or driving the biology for my tumor so that we can kind of identify prognostic development subtypes that can guide chair, um, and and therapy relevant sub types that can guide um in growth uh drug therapy choices, um, but also, um, test those in the lab first and kind of try to generate the evidence that those potential vulnerabilities, um, do lead to association with response to trauma. And that's a key part of the biomarker and personalized therapy. Um, uh, commentary that you heard today, really the underpinning of that is looking at specific alterations of the tumor, um, and you know, by the understanding how we apply that to predicting which patient is mostly responsible. Um, if you're in a research control, I was wondering what percent law versus that using around the problem, you know, to actually keep getting that into the information. It's a great question. Um, so we have Stage date for some growth like cell phase and vivo stage gate, so on. So first that is not new target so somebody not allowed in the research community hypothesis test and tested in a number of different crores cell lines and second growth five crores cell lines be able to positive testing together make decisions and invest in testing therapy. Understand those system trial backpackings and mouse studies are basically a lot of time as one we have the drug processing three quarter of the mouse number yet when we order. Advisory. So, uh, in our scientific advisory experts in the field, we'll review the name together with us and we'll make it a fleet position on whether this is strong enough for, um, investing in a clinical cloud or not. So generally that's how the process works. And, um, you know, if we're already in discussions of the company, then we're starting to think about blocks. Oh, sorry. This is the last question. May, um, also And now that we all read that rate area, again you have very similar models being, you know, advanced. So it's quickly not Um, block on the side, but there's three emerging opportunities to target break period, and then there's three active drugs currently, um, for patients that are not related to targeting break period. There's a term harvesting, um, drugs in broadly bar and there's maps lines of therapy, and there's permetrics. Those are the three kind of that I was referring to.